Table 1 Comparing patients under diagnostic-driven therapy with voriconazole and those under empiric antifungal therapy without voriconazole

Age (years), median (range)

63 (23–81)

51 (14–80)

Gender, male

26 (59)

131 (59)

Diagnosis of IA

 Definite IA

4/43 (9)

83 (38)

 Probable IA

39/43 (91)

138 (62)

Invasive pulmonary infection^a

40 (91)

178 (81)

Disseminated infection^a

2 (5)

18 (8)

Localized or sinus infection^a

4 (9)

28 (13)

Leukemia

19 (43)

181/220 (82)

Lymphoma

16 (36)

34/220 (15)

Myeloma

8 (18)

5/220 (2)

Transplantation within 1 year prior to infection

16 (36)

82/220 (37)

Type of transplantation within prior year

 Allogeneic transplant

10/16 (63)

74/82 (90)

 Autologous transplant

6/16 (38)

8/82 (10)

Graft vs Host Disease (GVHD)

8/10 (80)

52/74 (70)

Neutropenia (< 500 ANC) at onset of IA

8/42 (19)

120/216 (56)

Persistent neutropenia

14/36 (39)

87/210 (41)

Received immunotherapy

10/43 (23)

154/220 (70)

Received WBC transfusion

2/42 (5)

45 (20)

Year of IA diagnosis/treatment

 1993–2004

8 (18)

162 (73)

 2005–2016

36 (82)

59 (27)

Prophylactic antifungal treatment prior to

7 (16)

78 (35)

infection

Breakthrough

6/7 (86)

67/78 (86)

Response to therapy

32 (73)

30 (14)

Death within 42 days of starting therapy

2 (5)

123/220 (56)

Aspergillosis-attributable death within 42 days of starting therapy

2 (5)

107/218 (49)